• Users Online: 296
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
ARTICLE
Year : 2011  |  Volume : 2  |  Issue : 4  |  Page : 273-279

Thromboprophylaxis in Cancer Patients Receiving Bevacizumab


1 The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY 12144 USA;
2 The Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, One Discovery Drive, Rensselaer, NY 12144 USA; College of Medicine, King Saud University, Riyadh, Saudi Arabia

Date of Web Publication30-Jun-2014

Correspondence Address:
Shaker A Mousa
Professor of Pharmacology, Vice Provost, Executive Vice President and Chairman, Pharmaceutical Research Institute at Albany College of Pharmacy and Health Sciences, 1 Discovery Drive (Room 238), Rensselaer, New York 12144, USA

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions
  Abstract 

Background: Thrombosis is one of the leading causes of death in cancer patients. Anti-angiogenic inhibitors like bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, increase the risk of thrombosis. Thromboprophylaxis must be provided to patients receiving bevacizumab.
Methods: An up-to-date, comprehensive literature search using PubMed for studies performed on bevacizumab from January 2003 to the present was performed. Key words searched included bevacizumab, avastin, thromboprophylaxis, and anticoagulation in cancer patients.
Results: Thrombosis risk is increased with bevacizumab therapy. Anticoagulation therapy with bevacizumab may increase bleeding risks; however, these risks are generally low and for minor bleeding. Current guidelines approve thromboprophylaxis in a subset of cancer patients; however, they are not specific for patients receiving anti-angiogenesis therapy.
Conclusion: Thromboprophylaxis should be considered for patients receiving bevacizumab, as the benefits outweigh the small risk of adverse effects such as bleeding.

Keywords: Angiogenesis inhibition, bevacizumab, avastin, chemotherapy, thromboprophylaxis, anticoagulation, cancer patients


How to cite this article:
Byun JY, Mousa SA. Thromboprophylaxis in Cancer Patients Receiving Bevacizumab. J Appl Hematol 2011;2:273-9

How to cite this URL:
Byun JY, Mousa SA. Thromboprophylaxis in Cancer Patients Receiving Bevacizumab. J Appl Hematol [serial online] 2011 [cited 2019 May 22];2:273-9. Available from: http://www.jahjournal.org/text.asp?2011/2/4/273/135580

.




 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
Abstract

 Article Access Statistics
    Viewed1166    
    Printed47    
    Emailed0    
    PDF Downloaded2616    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]